Learn more about Lundbeck's mid- to late-stage development program (phase 1 projects are not included).
Underlying disease biology
Lundbeck’s research and development is aimed at enabling the discovery and development of new pharmaceuticals targeting the underlying mechanisms of brain diseases. This requires comprehensive research in the biology and the mechanisms of the diseases, as well as improved understanding of research targets and clinical outcomes. Over the years, we have built a broad and robust platform within psychiatry and neuro-degeneration, which allows us to use small molecules, antibodies and vaccines in the development of new medicines that can treat symptoms more effectively and potentially also alter the course of the diseases.
Read more about our research and development focus on our H. Lundbeck A/S website.